SCHEMBL15919273

SCHEMBL15919273

Fc1ccc(-c2ccc(-c3cc(Br)c4cnccc4n3)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.47
ESR2 Q92731 3/20 0.47
ESRRB O95718 1/20 0.47
ESRRA P11474 1/20 0.47
ALDH1A1 P00352 2/20 0.44
TOP1 P11387 2/20 0.44
GAA P10253 1/20 0.44
PKM P14618 1/20 0.42
CYP19A1 P11511 1/20 0.42
CSNK2A2 P19784 1/20 0.41
CSNK2B P67870 1/20 0.41
DHODH Q02127 4/20 0.41
KDM4E B2RXH2 1/20 0.38
AR P10275 1/20 0.38
MAPK14 Q16539 2/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15919444 0.82 ALDH1A1 (0.47) ALDH1A1TOP1GAAPKMCYP19A1
SCHEMBL14034409 0.81 MAPK14 (0.48) ALDH1A1TOP1GAAPKMCYP19A1
SCHEMBL4857363 0.81 ALDH1A1 (0.48) ALDH1A1TOP1GAAPKMCYP19A1
SCHEMBL4247635 0.81 ACHE (0.49) ALDH1A1TOP1GAAPKMCYP19A1
SCHEMBL4252230 0.77 ALDH1A1 (0.69) ALDH1A1GAACSNK2A2CSNK2BDHODH
SCHEMBL15905546 0.74 GAA (0.53) ALDH1A1GAADHODHKDM4EMAPT
SCHEMBL20547432 0.73 LATS1 (0.56)
SCHEMBL15905517 0.73 PIM1 (0.49) ALDH1A1TOP1GAADHODHKDM4E
SCHEMBL15919258 0.72 LATS1 (0.46) ALDH1A1GAAPKMCYP19A1CSNK2A2
SCHEMBL10725104 0.72 AXL (0.40) CSNK2A2CSNK2BDHODHKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO ESR1 1463/4885ESR2 1372/4885ESRRB 1376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.